GBGregory S. Basarab

Gregory S. Basarab

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Gregory S. Basarab has a total of 233 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Investigating the Domain Selectivity of Dual Inhibitors of Angiotensin I-Converting Enzyme and Neprilysin

    by Joanna ŻuKowska, Gyles E. Cozier, Lauren B. Coulson, Charles J. Eyermann, Gregory S. Basarab, Sylva L. Schwager, Kelly Chibale, Edward D. Sturrock, K. Ravi Acharya

    Cardiovascular diseases, driven primarily by hypertension, depend on blood pressure regulation through the renin-angiotensin-aldosterone system (RAAS), endothelin system (ES), and natriuretic peptide and kinin system (NPKS). These pathways require balanced peptide processing by enzymes such as angiotensin-converting enzyme (ACE) and neprilysin (NEP). Current antihypertensive therapies inhibit both the N-domain (nACE) and C-domain (cACE) of ACE, often causing undesirable side effects. To address this, cACE-selective inhibitors have been developed, while simultaneous inhibition of cACE and NEP has demonstrated improved pharmacological efficacy in hypertensive mice. Enzyme kinetic analyses and X-ray crystallography identified three dual cACE/NEP inhibitors (AD017, AD018, and AD019), each exhibiting approximately 10-fold selectivity for cACE over nACE. Notably, AD019 combined this cACE selectivity with low-nanomolar NEP inhibition, making it the most promising lead. These findings demonstrate that hydrophobic P1/P1′ residues and a bulky aromatic P2′ group optimally exploit the hydrophobic subsites of cACE and NEP for drug design.

  • Open Access

    Small-molecule IGF1R inhibitors extend healthspan in a mouse model

    by Yulia Balandina, Tom Stadnikov, Gregory Basarab, Charles J. Eyermann, Alexander Suvorov

    Antagonistic pleiotropy of the IGF-1 signaling cascade is well recognized, as it promotes growth and development at younger ages and delays aging later in life. The goal of this study is to test in a mouse longevity experiment whether orally delivered small-molecule IGF1R inhibitors have promise as an anti-aging therapy. C57BL/6 mice (25 male and 25 female mice per treatment) were treated with selective IGF1R inhibitors, picropodophyllin (PPP) or 5-[3-(phenylmethoxy)phenyl]-7-[trans-3-(1-pyrrolidinylmethyl)cyclobutyl]-7H-pyrrolo[3-d]pyrimidin-4-amine (NVP-ADW742), via powdered diets starting at 13 months of age, and physiological and behavioral parameters, as well as survival, were assessed. Both compounds protected both sexes from short-term memory decline; reduced systolic blood pressure in males and pulse rate in both sexes; rescued declining glucose tolerance in males; and abolished grey hair development, reduced frailty, and protected against decline in grip strength in female mice. There were no sex differences in survival curves within groups. No significant differences between groups were observed in the Kaplan-Meier analysis. However, the survival curve in the NVP-ADW742 group was squarer than in controls, indicating a 93-day longer healthspan (p = 0.02). PPP treatment was associated with toxicity (GI bleeding). Additional analysis of the drug likeness of NVP-ADW742 demonstrated potential cardiotoxicity and brain bioaccumulation. To conclude, small-molecule IGF1R inhibitors hold promise as a therapy that may improve human health span and lifespan; however, both molecules tested in this study have side effects that may outweigh their anti-aging effects.

  • Identification of Compound 15 (MMV1581361) as a Pf ATP4 Inhibitor with Transmission-Blocking Activity and In Vivo Efficacy in a SCID Mouse Model of Malaria

    by Henry A. Onyame, Stephen Brand, Delphin Baud, Gregory S. Basarab, Natalie Hawryluk, Stacie Canan, Magdalene D. Togoh, Ramatu Abdulai, Robert Eduku, Mohammed Awal, et al.

    Focused structure-activity-relationship studies of MMV020136, 1, a whole-cell phenotypic screening hit originating from the Pathogen Box against the human malaria parasite, Plasmodium falciparum, led to the identification of compound 15 (MMV1581361). Compound 15 retained nanomolar activity against drug-sensitive, drug-resistant, and field isolates of Plasmodium falciparum blood-stage parasites. It was found to display a moderate rate-of-kill profile similar to pyrimethamine in vitro and efficacy in the humanized P. falciparum Pf3D70087/N9 NODscidIL2Rγnull mouse model at a single dose of 25 mg/kg, with similar kinetics to chloroquine. Furthermore, compound 15 demonstrated significant transmission-blocking potential, achieving 90% inhibition of male gamete exflagellation, a 98% reduction in mean oocyst intensity, and an 88% block in transmission. Mechanism-of-action studies revealed that compound 15 disrupts Na+ ion homeostasis in P. falciparum, indicating that it functions as a PfATP4 inhibitor. However, due to the resistance risk associated with the PfATP4 target and the presence of more advanced clinical candidates, further development of 15 into a viable antimalarial drug is currently deprioritised.


  • Open Access

    Negamycin: Nature’s Forgotten Antibiotic

    by Grant A. Boyle, Gregory S. Basarab

    Negamycin is a natural product antibiotic discovered in 1970 and shown to have a Gram-negative spectrum of activity. It has served as the starting point in drug discovery efforts due in large part to its structural simplicity and novel mode of inhibition of the bacterial ribosome. It follows that negamycin does not show cross-resistance with other antibacterial agents that operate on the ribosome, whether this would be due to target modification, drug efflux, or drug metabolism. Because of the deficiencies of current drug regimens for the treatment of infections caused by Gram-negative pathogens, having a new agent brought to the infectious disease formulary represents a critical medical need, as has been promoted by the World Health Organization and other entities. Negamycin has been the subject of over 20 total syntheses, often highlighting stereoselective chemistry toward installing its two chiral centers on an acyclic chain. Novel synthetic methodologies thereby developed can stimulate the synthesis of novel analogs. With this, progress has been made in devising more potent analogs than negamycin. Structural work has determined that negamycin binds to the A-site of the 30S ribosome encounter complex with tRNA. Advancements have been made to understand the mechanism of transport of negamycin to the bacterial cytoplasm to enable engagement of the ribosome. This review surveys much of what has been published around negamycin and its analogs, including aspects of the biological spectrum of activity and mode of action as well as limitations that have held back clinical development.

  • Open Access

    A Novel Class of Orally Bioavailable Phenylglycine–Benzoxaborole Conjugates with Antimalarial Activity and Potentially Novel Mechanism of Action

    by Mokhitli Morake, Dale Taylor, Dina Coertzen, Mathew Njoroge, Liezl Krugmann, Meta Leshabane, Shanté da Rocha, Tarrick Qahash, Gareth Girling, Rachael Coyle, et al.

    A new class of benzoxaboroles with a phenylglycine appendage was found to display in vitro blood stage activity against the human malaria parasite Plasmodium falciparum (Pf). Structure-activity relationship studies of the starting hit compound 3 resulted in compounds active against PfNF54 drug-sensitive and PfK1 drug-resistant strains with an in vitro antiplasmodium IC50 < 0.4 μM, selectivity over mammalian cell-lines (selectivity index > 47) and high aqueous solubility (160 to >200 μM). Selected compounds showed good in vitro metabolic stability when incubated with human, rat, and mouse liver microsomes and showed no cross-resistance against barcoded mutant lines. Two frontrunner compounds, 6 and 7, were dosed orally at 50 mg·kg-1 using a standard quadrupole dosing regimen in a P. berghei mouse infection model and showed encouraging in vivo efficacy. This work identifies a promising new class of phenylglycine-based benzoxaboroles, which warrants further medicinal chemistry optimization.

  • Open Access

    Optimization of 2,8-Diaryl-1,5-naphthyridines as Plasmodium falciparum Phosphatidylinositol 4-Kinase Inhibitors with Improved ADME Profiles and In Vivo Efficacy

    by Godwin A. Dziwornu, Donald Seanego, Stephen Fienberg, Venkata S. Sypu, Nicolaas Salomane, Liezl Krugmann, Dale Taylor, Keabetswe Masike, Mathew Njoroge, Nonlawat Boonyalai, et al.

    Previously reported antimalarial Plasmodium phosphatidylinositol 4-kinase IIIβ 2,8-diaryl-1,5-naphthyridine inhibitors have shown suboptimal physicochemical and pharmacokinetic properties. A focused target-based structure–activity relationship and structure–property optimization studies identified several compounds with good target and whole-cell activities and improved physicochemical properties. A new frontrunner compound 27 showed an improved pharmacokinetic profile and reduced parasitaemia (91% at 4 × 50 mg/kg QD doses) in the humanized NOD-scid IL-2Rγnull mouse model of Plasmodium falciparum malaria. Compound 27 poses no hERG channel inhibition at high concentrations or mammalian cytotoxicity but shows low selectivity against related human lipid kinases (PI3Kα and PI4Kβ); however, significantly higher selectivity margins were observed against the human MINK1 and MAP4K4 kinases.


  • Open Access

    Cell-Based Progression of Spiroindoline Phenotypic Hits Leads to the Identification of Compounds with Diverging Parasitological Profiles against the Human Malaria Parasite Plasmodium falciparum

    by Jean Dam, Grant A. Boyle, André Horatscheck, John G. Woodland, Claire Le Manach, Gurminder Kaur, Dale Taylor, Liezl Krugmann, Mathew Njoroge, Nina Lawrence, et al.

    In the search for novel chemotypes with high sp3 character and activity against the human malaria parasite Plasmodium falciparum, a spiroindoline series was identified from a phenotypic high-throughput screening campaign. The spiroindoline hit 2 displayed good activity against both drug-sensitive and multidrug-resistant Plasmodium strains, making it an attractive starting point for hit-to-lead progression. Structure-activity relationship studies led to the identification of a novel pyridylspiroindoline frontrunner (50) with improved antiplasmodial activity, aqueous solubility, and microsomal metabolic stability. Data from additional parasitological profiling suggested that 50 likely has a mode of action differing from that of the original spiroindoline hit. Compound 50 showed excellent in vivo pharmacokinetics with efficacy being achieved in a humanized immunodeficient NSG mouse P. falciparum infection model. This provided a pharmacological proof-of-concept for this series, making it a valuable starting point for further optimization in the quest for novel antimalarial therapeutics.


  • Open Access

    Design of Novel Mercapto-3-phenylpropanoyl Dipeptides as Dual Angiotensin-Converting Enzyme C–Domain-Selective/Neprilysin Inhibitors

    by Gyles E. Cozier, Lauren B. Coulson, Charles J. Eyermann, Gregory S. Basarab, Sylva L. Schwager, Kelly Chibale, Edward D. Sturrock, K. Ravi Acharya

    Dual angiotensin-converting enzyme (ACE) and neprilysin (NEP) inhibitors such as omapatrilat showed promise as potent treatments for hypertension but produced adverse effects due to their high affinity for both domains of ACE (nACE and cACE). This led to the search for compounds that retained NEP potency but selectively inhibit cACE, leaving nACE active to degrade other peptides such as bradykinin. Lisinopril-tryptophan (LisW) has previously been reported to have cACE selectivity. Three mercapto-3-phenylpropanoyl inhibitors were synthesized, combining features of omapatrilat and LisW to probe structural characteristics required for potent dual cACE/NEP inhibition. We report the synthesis of these inhibitors, enzyme inhibition data, and high-resolution crystal structures in complex with nACE and cACE. This provides valuable insight into factors driving potency and selectivity and shows that the mercapto-3-phenylpropanoyl backbone is significantly better for NEP potency than a P1 carboxylate. Future chemistry efforts could be directed at identifying alternative chemotypes for optimization of cACE/NEP inhibitors.


  • Dose-fractionation studies of a Plasmodium phosphatidylinositol 4-kinase inhibitor in a humanized mouse model of malaria

    by Liezl Gibhard, Mathew Njoroge, Mwila Mulubwa, Nina Lawrence, Dennis Smith, James Duffy, Claire Le Manach, Christel Brunschwig, Dale Taylor, Renier van der Westhuyzen, et al.

    UCT594 is a 2-aminopyrazine carboxylic acid Plasmodium phosphatidylinositol 4-kinase inhibitor with potent asexual blood-stage activity, the potential for interrupting transmission, as well as liver-stage activities. Herein, we investigated pharmacokinetic/pharmacodynamic (PK/PD) relationships relative to blood-stage activity toward predicting the human dose. Dose-fractionation studies were conducted in the Plasmodium falciparum NSG mouse model to determine the PK/PD indices of UCT594, using the in vivo minimum parasiticidal concentration as a threshold. UCT594 demonstrated concentration-dependent killing in the P. falciparum -infected NSG mouse model. Using this data and the preclinical pharmacokinetic data led to a low predicted human dose of <50 mg. This makes UCT594 an attractive potential antimalarial drug.


  • Open Access

    Interactions between Zoliflodacin and Neisseria gonorrhoeae Gyrase and Topoisomerase IV: Enzymological Basis for Cellular Targeting

    by Jessica A. Collins, Gregory S. Basarab, Kelly Chibale, Neil Osheroff

    Gyrase and topoisomerase IV are the cellular targets for fluoroquinolones, a critically important class of antibacterial agents used to treat a broad spectrum of human infections. Unfortunately, the clinical efficacy of the fluoroquinolones has been curtailed by the emergence of target-mediated resistance. This is especially true for Neisseria gonorrhoeae, the causative pathogen of the sexually transmitted infection gonorrhea. Spiropyrimidinetriones (SPTs), a new class of antibacterials, were developed to combat the growing antibacterial resistance crisis. Zoliflodacin is the most clinically advanced SPT and displays efficacy against uncomplicated urogenital gonorrhea in human trials. Like fluoroquinolones, the primary target of zoliflodacin in N. gonorrhoeae is gyrase, and topoisomerase IV is a secondary target. Because unbalanced gyrase/topoisomerase IV targeting has facilitated the evolution of fluoroquinolone-resistant bacteria, it is important to understand the underlying basis for the differential targeting of zoliflodacin in N. gonorrhoeae. Therefore, we assessed the effects of this SPT on the catalytic and DNA cleavage activities of N. gonorrhoeae gyrase and topoisomerase IV. In all reactions examined, zoliflodacin displayed higher potency against gyrase than topoisomerase IV. Moreover, zoliflodacin generated more DNA cleavage and formed more stable enzyme-cleaved DNA-SPT complexes with gyrase. The SPT also maintained higher activity against fluoroquinolone-resistant gyrase than topoisomerase IV. Finally, when compared to zoliflodacin, the novel SPT H3D-005722 induced more balanced double-stranded DNA cleavage with gyrase and topoisomerase IV from N. gonorrhoeae, Escherichia coli, and Bacillus anthracis. This finding suggests that further development of the SPT class could yield compounds with a more balanced targeting against clinically important bacterial infections.